Asked Oct 12, 11:46 AM EDT (midday). Muse Spark 1.1, Perplexity, Gemini 1.5 Pro, Grok 4.5, DeepSeek and GPT-6 answered the same standard prompt independently. Window: from Oct 12, 11:46 AM EDT to Oct 13, 11:46 AM EDT, the same time one session later. Benchmark: SPY.
Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.
| Model | Correct | Hit rate | Return | SPY | Directional return |
|---|---|---|---|---|---|
| Muse Spark 1.1 | 2/5 | 40.00% | -0.95% | -0.30% | -0.95% |
| Perplexity | 5/5 | 100.00% | 1.38% | -0.30% | 1.38% |
| Gemini 1.5 Pro | 3/5 | 60.00% | -0.04% | -0.30% | -0.04% |
| Grok 4.5 | 5/5 | 100.00% | 2.92% | -0.30% | 2.92% |
| DeepSeek | 2/5 | 40.00% | -0.82% | -0.30% | -0.82% |
| GPT-6 | 3/5 | 60.00% | -0.29% | -0.30% | -0.29% |
Muse Spark 1.1
View full picks and reasoning
Market on Oct 12 is digesting a 【entity-SpaceX¦canonical_name=SpaceX】 $8B low-band spectrum purchase that repriced tower vs carrier names, plus a sticky Michigan inflation expectations print at 4.7% one-year. Top movers from Friday and premarket Monday show sharp rotation: towers and biotech up, wireless carriers down. Biotech momentum in MRNA on NIH cancer vaccine acceleration looks substantive. With bank earnings and CPI/PPI ahead, mean-reversion risk is high for the most extended moves.
- HUM up — confidence 68%. Source session gain ~+11.56% to $387.12 close per Simply Wall St top movers list, confirmed by InvestorPlace quote showing $437.60 intraday Oct 12 after prior close $387.12 and new 52-week high $456.50. Catalyst substantive: Medicare Advantage star rating upgrade to 4 stars restores bonus payment eligibility, plus Baird upgrade to outperform with $596 target. Market cap ~46.49B exceeds $1B, avg vol ~4.99M shares * price implies >$2B dollar volume, well above $20M. Reference price is live delayed quote Oct 12 morning, freshness ~30 min. Continuation up likely as quality ratings directly affect 2027 revenue.
Return: -1.94%; alpha: -1.63%. - CCI down — confidence 62%. Source session +15.60% to $79.64 close per Zacks/Simply Wall St, attributed to SpaceX ~$8B 800MHz spectrum deal keeping door open for ground network needing tower space. Catalyst mix of substantive and speculative: tower leasing opportunity real but magnitude unclear, short squeeze after -22% YTD decline. Price $79.84 Oct 12 10:39 AM EDT open per stockanalysis.com, previous close $79.64. Market cap $33.97B per stockanalysis as of Oct 12, avg volume 3.43M shares per finsuba (~$274M dollar volume) >$20M. Reversal down expected after parabolic 20.96% 5-day return, overbought.
Return: -0.25%; alpha: 0.55%. - MRNA up — confidence 65%. Source session +14.21% to $225 close per Simply Wall St top movers, catalyst substantive: NIH initiative to accelerate cancer vaccine development plus index inclusion. Confirmed by Robinhood snapshot $225.51 Oct 12 with market cap 89.82B and avg daily volume 19.21M shares (~$4.3B dollar volume). 5-day return +14.54% per Finnhub. Reference price is live intraday $225.52. Continuation up likely as mRNA pipeline re-rated, volume >28M on breakout indicates institutional interest.
Return: -1.44%; alpha: -1.13%. - TMUS up — confidence 60%. Source session -13.27% top loser per Simply Wall St, catalyst speculative selloff on SpaceX spectrum purchase plus store closures and plan changes. Price fell to $148.58 previous close, now $152.64 Oct 12 +2.73% bounce per Finnhub with open $149.6. Market cap ~$203.03B per MarketBeat, avg volume ~5.79M shares (~$880M dollar volume) exceeds floor. Raymond James upgraded to outperform $170 target Oct 12, Scotiabank cut to $212 still above market, suggesting oversold. Reversal up expected.
Return: 0.82%; alpha: 1.12%. - T down — confidence 58%. Source session -10.82% top loser per Simply Wall St on 【entity-SpaceX¦canonical_name=SpaceX】 wireless push concern alongside 【entity-AT&T¦canonical_name=AT&T】 mobile pricing moves. Closed $22.18 Friday per MarketBeat, now $22.29 +0.49% Oct 12 per Finnhub. Market cap $151.97B to $170.38B per MarketBeat/Finnhub, avg volume 74M shares 20-day per Barchart implies ~$1.6B dollar volume >$20M. Price >=$5 passes. Continuation down likely as carrier multiple compression continues into earnings with rate sensitivity.
Return: 2.44%; alpha: -2.14%.
Perplexity
View full picks and reasoning
The source session was Friday, October 9, 2026, when SpaceX's nationwide low-band spectrum acquisition triggered a sharp telecom-infrastructure rotation: tower REITs rallied while wireless carriers and satellite-connectivity names sold off. With the next session opening after a holiday-thinned tape and ahead of bank earnings, I favor partial mean reversion in the largest one-day moves rather than unconditional continuation, while recognizing that the SpaceX catalyst may keep pressuring carriers.
- CCI down — confidence 55%. Crown Castle was the largest S&P 500 gainer in the October 9 source session, rising 15.60% to $79.64 after SpaceX's spectrum deal was read as supportive for tower-leasing demand. The catalyst is substantive but already produced an outsized one-day repricing; I expect some reversal lower as the initial news premium is digested. Reference price is the latest quote found, $79.80 on October 12, 2026; market cap and 20-day dollar volume were verified from quote pages showing a $33.88-34.65 billion market cap and roughly 3.78-4.59 million average daily shares, implying well over $20 million in daily dollar volume.
Return: -0.25%; alpha: 0.55%. - MRNA down — confidence 50%. Moderna gained 14.21% in the source session, closing at $225.00, on an NIH cancer-vaccine initiative and index-inclusion-driven biotech enthusiasm. The catalyst appears partly speculative and event-driven rather than a confirmed near-term earnings change, so I expect a reversal lower after the outsized advance. The latest quote found was $225.47 on October 12, 2026; market cap was about $89.82 billion and average volume 19.21 million shares, comfortably clearing the liquidity floor.
Return: -1.44%; alpha: 1.74%. - HUM down — confidence 50%. Humana rose 11.56% to $431.87 in the October 9 session after improved Medicare Advantage star ratings and analyst upgrades reset earnings expectations. This is a more fundamental catalyst than a purely speculative move, but the size of the single-day gain argues for partial reversal. The latest quote found was $438.49, dated October 11, 2026 on the quote snapshot; market cap was about $51.85 billion and average volume 1.94 million shares, implying roughly $850 million of daily dollar volume.
Return: -1.94%; alpha: 2.24%. - TMUS up — confidence 55%. T-Mobile US fell 13.27% to $148.58 in the source session after SpaceX's spectrum acquisition and store-closure plans refocused investors on competitive risk. The threat is substantive, but the decline was exceptionally large for a mega-cap carrier and the stock was indicated about 1.15% higher in the October 12 premarket; I expect a partial reversal higher. The latest quote found was $148.76 on October 12, 2026; market cap was about $159.39 billion and average volume 5.63 million shares, implying roughly $838 million of daily dollar volume.
Return: 0.82%; alpha: 1.12%. - T up — confidence 50%. AT&T declined 9.70% to $22.18 in the October 9 source session on SpaceX-related competitive concerns, an ex-dividend date, and an Oppenheimer downgrade. The fundamental concern is real, but the move was severe for a large, dividend-paying telecom and the stock was indicated modestly higher in the October 12 premarket; I expect a partial reversal higher. The latest quote found was $22.24 in premarket trading on October 12, 2026; market cap was about $151.99 billion and average volume roughly 49.69 million shares, implying more than $1.1 billion of daily dollar volume.
Return: 2.44%; alpha: 2.75%.
Gemini 1.5 Pro
View full picks and reasoning
The broader US market started the week on a cautious and mixed note as investors weigh escalating Middle East geopolitical tensions, an uptick in Brent crude prices beyond $106 per barrel, and key incoming economic reports alongside the imminent start of the Q3 corporate earnings season led by major banks. This backdrop fosters stock-specific momentum over broad beta, rewarding fundamental catalysts like acquisitions, clinical trial readouts, and analyst upgrades while punishing high-valuation names experiencing profit-taking.
- CCC up — confidence 80%. CCC Intelligent Solutions shares surged during the source session driven by reports indicating buyout and takeover interest in the software firm, with private equity and potentially Copart among the speculated suitors. This substantive catalyst drove robust buying. I expect this upward momentum to continue in the near term as acquisition premium expectations solidify. Note: The exact 20-day average dollar volume could not be confirmed, so it is omitted; however, the intraday volume of over 14 million shares at ~$7.70 easily clears the $20M threshold. Live intraday quote used.
Return: 0.97%; alpha: 1.28%. - TRAX up — confidence 75%. First Tracks Biotherapeutics climbed sharply following positive Phase 1b results for ANB033 in a celiac disease gluten-challenge study, demonstrating statistically significant benefits. This clinical validation provides a strong substantive catalyst for further upside. I project continuation of this trend as market participants digest the pipeline implications. Note: The exact 20-day average dollar volume could not be confirmed, so it is omitted, but recent trading volumes combined with a ~$35 share price easily exceed the $20M floor. Intraday quote used.
Return: -6.48%; alpha: -6.18%. - BIIB up — confidence 70%. Biogen gained traction during the session following an upgrade to Overweight from Neutral by JPMorgan, which highlighted a promising pipeline of catalysts heading into 2027 and issued a $300 price target. This analyst conviction should encourage near-term accumulation, leading to a continuation of the upward trajectory. Note: The precise 20-day average dollar volume could not be confirmed and is thus omitted, though an average volume of ~1M shares at ~$230 clearly exceeds $20M. Delayed intraday quote used.
Return: -2.53%; alpha: -2.23%. - BE down — confidence 65%. Bloom Energy shares sank following a massive recent run-up, as investors took profits and digested cautious analyst commentary ahead of their upcoming earnings report. The combination of high current valuation metrics and profit-taking represents a substantive headwind. I expect this downward retracement to continue. Note: The exact 20-day average dollar volume was unverified and omitted, but typical trading liquidity for an $80B market-cap constituent significantly surpasses the $20M mark. Delayed quote used.
Return: -3.42%; alpha: 3.72%. - IONQ down — confidence 60%. IonQ shares slipped after the quantum computing firm announced an agreement to acquire cybersecurity company Elisity in an all-stock transaction valued at up to $1.3 billion. The market's initial reaction to the dilution risk and integration uncertainty represents a substantive negative catalyst. I forecast a continuation of the downward pressure in the near term as investors reprice the equity post-deal announcement. Note: The exact 20-day average dollar volume is omitted as it could not be confirmed precisely, but standard volume metrics easily clear the $20M minimum. Delayed intraday quote used.
Return: -4.40%; alpha: 4.71%.
Grok 4.5
View full picks and reasoning
US equities are mixed midday on October 12 with tech and optical communications names under pressure while select software and apparel names outperform. Liquidity is adequate in the selected large- and mid-cap names; catalysts appear mostly speculative or sector-sympathy rather than company-specific fundamentals for the session moves.
- CCC up — confidence 62%. CCC is among the top liquid gainers on the session with a roughly 9.9 percent rise on elevated volume. Prior-session change is positive so the hypothesis is continuation higher. Takeover chatter involving private-equity interest provides a speculative catalyst that may sustain momentum into the next session. Reference price is the latest intraday quote near midday EDT; market-cap and 20-day dollar-volume floors are comfortably cleared. Risk is that the move fades if no deal materializes.
Return: 0.97%; alpha: 1.28%. - FIGS up — confidence 58%. FIGS ranks among the stronger liquid gainers with an approximate 9 percent advance. Positive prior-session change supports a continuation thesis. No major fundamental catalyst is evident beyond broader apparel strength and technical follow-through. Latest traded price used is the midday intraday quote; market-cap exceeds 2.5 billion and average dollar volume clears the 20 million threshold. Risk is mean-reversion after a multi-day run.
Return: 3.53%; alpha: 3.83%. - TTMI down — confidence 60%. TTMI is a top loser with a roughly 10 percent decline after announcing large strategic investments. Negative prior-session change supports continuation lower. The investment news is substantive but the market is treating the near-term capital outlay as a negative. Reference price is the latest midday intraday print; market-cap is above 11 billion and average dollar volume exceeds 200 million. Risk is a relief bounce if the investment is reframed positively.
Return: -0.33%; alpha: 0.63%. - CIEN down — confidence 55%. CIEN is among the larger-cap optical/comms losers with an approximate 9 percent drop. Negative prior-session change supports continuation. The move appears driven by sector rotation and profit-taking rather than company-specific news. Latest traded price is the midday intraday quote; market-cap exceeds 58 billion and average dollar volume is well above the floor. Risk is a technical bounce given the magnitude of the decline.
Return: -5.07%; alpha: 5.38%. - LITE down — confidence 57%. LITE is a high-priced optical-components loser with a roughly 9.4 percent decline. Negative prior-session change supports continuation. Sector-wide pressure on AI-related optical names appears to be the main driver and is largely speculative. Reference price is the latest midday intraday quote; market-cap is near 90 billion and average dollar volume is several billion. Risk is short-covering given extreme recent gains preceding today.
Return: -4.70%; alpha: 5.01%.
DeepSeek
View full picks and reasoning
US equities are mixed as memory-chip weakness pressures semiconductors while select large-cap technology and healthcare names attract buyers. The S&P 500 is roughly flat, the Dow is slightly higher, and the Nasdaq is marginally lower. Sector rotation is evident, with money flowing into communication services and medical devices while storage and power-semiconductor names face selling pressure. The market is digesting a mix of company-specific catalysts and macro crosscurrents, and next-session direction will likely hinge on whether the memory selloff stabilizes and whether positive corporate news can sustain momentum.
- META up — confidence 72%. Meta Platforms gained 3.70% in the source session, driven by reports that its Muse AI product retains users at levels close to ChatGPT. This is a substantive product-level catalyst that supports the bull case for Meta's AI monetization. The stock is a large-cap liquid name with a market cap of $1.83T and deep average dollar volume. The latest intraday quote is $745.07 as of October 12, 2026, 10:44 AM EDT. The direction is up on a continuation hypothesis, as the positive engagement data is likely to sustain buying interest into the next session.
Return: 2.14%; alpha: 2.44%. - FIGS up — confidence 68%. FIGS rose 3.80% in the source session on reports of stronger customer engagement and an improved bull case. The catalyst is somewhat speculative, relying on consumer sentiment rather than hard financial data, but the stock trades at $16.38 intraday on October 12, 2026, and has a market cap of approximately $2.62B. Average 20-day volume of ~2.81M shares gives a dollar volume of roughly $46M, comfortably above the floor. The pick is a continuation-up, as the engagement narrative may carry momentum.
Return: 3.53%; alpha: 3.83%. - WOLF up — confidence 65%. Wolfspeed fell 7.50% in the source session despite substantive positive news: a conditional $1.5B, 30-year loan from the U.S. Department of War to expand silicon-carbide semiconductor production, plus a partnership with Geener Microelectronics. The selloff appears driven by sector-wide weakness rather than company-specific deterioration, making this a reversal candidate. The intraday quote is $28.315 on October 12, 2026, with a market cap of $1.62B and average 20-day dollar volume of approximately $109M. Direction up, hypothesis reversal.
Return: -0.44%; alpha: -0.14%. - SNDK up — confidence 62%. SanDisk tumbled 6.74% in the source session amid memory-oversupply fears and a broad storage-chip selloff. The decline looks speculative and sector-driven rather than tied to company-specific fundamentals, which favors a reversal. The stock is highly liquid with a $228.62B market cap and average 20-day volume of 12.72M shares. The latest intraday quote is $1,502.69 on October 12, 2026, reflecting a 5.00% decline during the session. Direction up, hypothesis reversal.
Return: -3.45%; alpha: -3.14%. - MU up — confidence 60%. Micron fell 3.54% in the source session on competition concerns from China's CXMT and broader memory-sector weakness. However, the company disclosed a $33B stock-repurchase authorization, a substantive positive that may support a rebound. The intraday quote is $982.57 on October 12, 2026, with a $1.16T market cap and average 20-day volume of 32.48M shares. The selloff appears sentiment-driven rather than fundamentally justified, favoring a reversal. Direction up, hypothesis reversal.
Return: -5.87%; alpha: -5.57%.
GPT-6
View full picks and reasoning
The October 9, 2026 source session featured unusually large, news-driven moves in telecommunications, wireless infrastructure, healthcare and technology. The broad market was positive, with the S&P 500 gaining approximately 0.6%, but individual stocks reacted much more dramatically to new information. SpaceX's $8 billion spectrum agreement created a credible long-term competitive threat to established wireless carriers and a potential opportunity for tower operators. Humana received materially improved Medicare Advantage star ratings, while Fastly rallied on an analyst upgrade and Novavax benefited from vaccine-related optimism. For the October 12-13 prediction window, the preferred approach is selective mean reversion where the initial reaction appears excessive, combined with continuation where a catalyst has measurable economic consequences. The five selections include four source-session gainers or losers with double-digit moves and one additional major gainer. All five exceed the $5 share-price, $1 billion market-capitalization and $20 million average daily dollar-volume thresholds using October 9 closing data. Market capitalizations are reported at their published October 9 precision. Average daily dollar volumes were independently calculated from the 20 regular trading sessions ending October 9, using each day's closing price multiplied by reported share volume, then averaging those 20 values. These dollar-volume figures are close-price-based estimates of trading value, not exchange-reported VWAP turnover. Reference prices are October 12 intraday observations, not October 9 closing prices. The primary evaluation is the mean signed return over the specified prediction window, with direction accuracy evaluated separately; neither metric represents alpha.
- TMUS up — confidence 69%. Rank 1 because Friday's 13.27% decline appears disproportionate to the immediate financial impact of SpaceX's wireless expansion. The substantive catalyst is SpaceX's approximately $8 billion agreement to acquire nationwide low-band spectrum from Grain Management. However, the threatened loss of T-Mobile customers and profits remains speculative because SpaceX still faces regulatory approvals, substantial network construction requirements and potentially years of deployment. Analysts have argued that immediate competitive exposure is limited. T-Mobile's established subscriber base, infrastructure and cash generation support a partial valuation recovery. The stock had already rebounded approximately 2.7% on October 12 by the observed quote, providing evidence of improving sentiment. The October 9 close was $148.58 versus $171.31 on October 8. The reference price is an October 12 intraday trade observed at 11:46 EDT, rather than a closing price. The October 9 market capitalization was approximately $159.38 billion. Risk: investors may continue assigning lower long-term multiples to incumbent carriers if SpaceX's strategic threat is considered structural rather than temporary. Catalyst evidence: https://www.reuters.com/business/what-is-low-band-spectrum-that-spacex-acquired-starlink-mobile-2026-10-09/ .
Return: 0.82%; alpha: 1.12%. - FSLY down — confidence 67%. Rank 2 because Friday's 15.86% rally followed an Oppenheimer upgrade to Outperform with a $35 price target, rather than a newly reported contract or realized earnings increase. The underlying AI-traffic and cybersecurity opportunities are substantive business themes, but their incremental financial contribution remains forecast-dependent. Fastly's valuation had already expanded substantially during 2026, increasing vulnerability to profit-taking after a sharp analyst-driven rally. Its October 12 trading weakness, approximately 8.3% below Friday's closing price at the observed quote, suggests that some of the immediate upgrade enthusiasm is fading. The October 9 close was $29.30 versus $25.29 on October 8. The reference price is an October 12 intraday observation at 11:42 EDT, not the previous close. The October 9 market capitalization was approximately $4.67 billion. Risk: additional analyst upgrades, short covering or growing expectations for AI-security revenue could quickly reverse the selloff. Catalyst evidence: https://www.fool.com/investing/2026/10/09/why-fastly-stock-is-soaring-today/ .
Return: -0.44%; alpha: 0.75%. - NVAX down — confidence 64%. Rank 3 because Novavax advanced 15.80% on October 9 amid renewed enthusiasm for biotechnology and vaccine developers, while its immediate company-specific earnings catalyst was less definitive than the price move. Regulatory progress associated with Sanofi's Phase 3 COVID-influenza combination vaccine program represents substantive progress, and a potential $125 million milestone could be financially meaningful. However, that payment remains contingent on future program developments. Earlier speculative interest surrounding a suspected plague case had already caused exceptional volatility before health authorities characterized the broader risk as low. Friday's rise also occurred alongside gains in Moderna and other biotechnology companies, indicating sector-wide sentiment rather than exclusively new Novavax fundamentals. The October 9 close was $12.75 versus $11.01 on October 8. The reference price is an October 12 intraday observation at 11:39 EDT, approximately seven minutes before the prediction timestamp, and is not a closing price. The October 9 market capitalization was approximately $2.10 billion. Risk: substantial short interest, positive partnership updates or renewed biotechnology momentum could produce another sharp rally. Catalyst evidence: https://ca.investing.com/news/stock-market-news/why-is-novavax-stock-surging-today-93CH-4873838 .
Return: 1.01%; alpha: -0.71%. - HUM up — confidence 61%. Rank 4 because Humana's October 9 rally has a more measurable fundamental catalyst than several other extreme movers. The company announced that 95% of its Medicare Advantage members were enrolled in plans carrying ratings of four stars or higher for 2027, compared with substantially lower proportions in preceding years. This creates a credible opportunity for improved quality-bonus eligibility and future profitability, although related payment benefits primarily materialize beyond the immediate trading window. Shares gained 11.56% on Friday, closing at $431.87 versus $387.12 on October 8. On October 12, the shares were trading lower despite the favorable announcement, potentially creating an opportunity for renewed buying following the initial profit-taking. The reference price is an October 12 intraday trade at 11:46 EDT, not Friday's close. The October 9 market capitalization was approximately $51.86 billion. Risk: the favorable ratings could already be reflected in valuation, while medical utilization, rising costs and broader Medicare reimbursement pressures could offset expected benefits. The continuation forecast is therefore moderate-confidence rather than high-confidence. Primary catalyst evidence: https://policy.humana.com/news-and-resources/news-press/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of .
Return: -1.94%; alpha: -1.63%. - CCI down — confidence 58%. Rank 5 because Crown Castle's October 9 gain of 15.60% appears to capitalize a substantial portion of a business opportunity that has not yet become confirmed contractual revenue. SpaceX's agreement to acquire low-band wireless spectrum is a substantive industry development, and a nationwide hybrid satellite-terrestrial network could require additional cellular tower infrastructure. However, the thesis that Crown Castle will become a major supplier to SpaceX remains speculative: no corresponding large-scale tower-leasing contract or quantified revenue commitment was verified. Crown Castle's existing leverage and exposure to high financing costs also limit the certainty of its rerating. The October 9 closing price was $79.64 versus $68.89 on October 8. The latest verified reference price was an October 12 intraday quote at 11:44 EDT, approximately two minutes before the prediction timestamp. The October 9 market capitalization was approximately $33.88 billion. Risk: further confirmation of Starlink Mobile's terrestrial infrastructure strategy, customer negotiations or additional analyst upgrades could maintain buying pressure and produce continuation instead of reversal. Catalyst evidence: https://www.investors.com/news/spacex-mobile-amt-cci-sbac-stock/ .
Return: -0.25%; alpha: 0.55%.
How models have done in Extreme Movers
ForecastNest's own settled Extreme Movers runs at this horizon, up to and including this one. Members' own research is not counted. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average directional return per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five directions were called correctly, which is a steadier measure on a short record because it counts several picks a run rather than one result.
Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.
| Model | Runs | Avg directions called correctly | Avg directional return |
|---|---|---|---|
| Claude Sonnet 5.5 | 8 | 55.00% | +0.82% |
| DeepSeek | 19 | 48.42% | +0.79% |
| Grok 4 | 2 | 50.00% | +0.31% |
| Gemini 3 Pro | 2 | 60.00% | +0.31% |
| Grok 4.5 | 14 | 47.14% | +0.25% |
| Claude Opus 5 | 6 | 60.00% | +0.03% |
| Claude Opus 5.5 | 3 | 33.33% | -0.24% |
| Perplexity | 12 | 45.00% | -0.30% |
| Muse Spark 1.1 | 17 | 38.82% | -0.36% |
| Gemini 1.5 Pro | 16 | 48.75% | -0.61% |
| GPT-6 | 7 | 42.86% | -1.86% |
| GPT-5.6 Sol | 10 | 46.00% | -3.06% |
View settlement prices
| Symbol | Start | End | Source | Notes |
|---|---|---|---|---|
| BE | 262.60000000 | 253.63000000 | https://finance.yahoo.com/quote/BE/history/ | |
| BIIB | 234.92000000 | 228.98000000 | https://finance.yahoo.com/quote/BIIB/history/ | |
| CCC | 7.70000000 | 7.77500000 | https://finance.yahoo.com/quote/CCC/history/ | |
| CCI | 80.28000000 | 80.08000000 | https://finance.yahoo.com/quote/CCI/history/ | |
| CIEN | 408.89500000 | 388.15000000 | https://finance.yahoo.com/quote/CIEN/history/ | |
| FIGS | 17.29000000 | 17.90000000 | https://finance.yahoo.com/quote/FIGS/history/ | |
| FSLY | 26.97990000 | 26.86000000 | https://finance.yahoo.com/quote/FSLY/history/ | |
| HUM | 427.29000000 | 419.02000000 | https://finance.yahoo.com/quote/HUM/history/ | |
| IONQ | 36.22500000 | 34.63000000 | https://finance.yahoo.com/quote/IONQ/history/ | |
| LITE | 1002.22500000 | 955.08120000 | https://finance.yahoo.com/quote/LITE/history/ | |
| META | 744.98000000 | 760.93000000 | https://finance.yahoo.com/quote/META/history/ | |
| MRNA | 216.71000000 | 213.60000000 | https://finance.yahoo.com/quote/MRNA/history/ | |
| MU | 996.50000000 | 938.00010000 | https://finance.yahoo.com/quote/MU/history/ | |
| NVAX | 12.40990000 | 12.53500000 | https://finance.yahoo.com/quote/NVAX/history/ | |
| SNDK | 1488.24000000 | 1436.94000000 | https://finance.yahoo.com/quote/SNDK/history/ | |
| SPY | 778.60000000 | 776.24500000 | https://finance.yahoo.com/quote/SPY/history/ | |
| T | 22.30500000 | 22.85000000 | https://finance.yahoo.com/quote/T/history/ | |
| TMUS | 152.58000000 | 153.83000000 | https://finance.yahoo.com/quote/TMUS/history/ | |
| TRAX | 34.71500000 | 32.46500000 | https://finance.yahoo.com/quote/TRAX/history/ | |
| TTMI | 108.73500000 | 108.37500000 | https://finance.yahoo.com/quote/TTMI/history/ | |
| WOLF | 27.24000000 | 27.12000000 | https://finance.yahoo.com/quote/WOLF/history/ |
Standard prompt extreme-movers-v11, SHA-256 32e39cf59d49647f7d352d1951a073ee2edd2b833424a673ad0fb3d0cfe62d66. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.
Calculation: extreme-movers-v1.